<DOC>
	<DOCNO>NCT01477749</DOCNO>
	<brief_summary>To demonstrate sipuleucel-T successfully manufactured subject metastatic castrate resistant prostate cancer ( mCRPC ) European manufacturing facility .</brief_summary>
	<brief_title>Sipuleucel-T Manufacturing Demonstration Study</brief_title>
	<detailed_description>This open-label , uncontrolled , multi-center study . Study participant underwent screening procedure ensure meet inclusion exclusion criterion . Subjects underwent standard 1.5 2.0 blood volume leukapheresis , follow approximately 3 day later infusion sipuleucel-T . This process repeat approximately 2-week interval total 3 infusion . In Austria , The Netherlands , France , study completion visit occur 30 37 day post-final infusion , 30 37 day post-final leukapheresis subject receive least 1 infusion . In UK , follow-up visit occur 30 day subject 's final infusion study completion visit occur 6 month subject 's final infusion .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Histologically document adenocarcinoma prostate Metastatic disease evidence soft tissue and/or bony metastases bone scan and/or compute tomography ( CT ) scan abdomen pelvis time prior registration Castrate resistant prostate cancer Serum PSA ≤ 5.0 ng/mL Castration level testosterone ( ≤ 50 ng/dL ; ≤ 1.74 nmol/L ) achieve via medical surgical castration . Surgical castration must occur least 3 month prior registration . ECOG performance status ≤ 1 Adequate hematologic , renal , liver function Negative serology test indicate active infection human immunodeficiency virus type 1 2 ( HIV1/2 ) , human T cell lymphotropic virus type 1 2 ( HTLVI/II ) , Hepatitis B C virus . The presence know brain metastases A requirement systemic immunosuppressive therapy reason Treatment investigational vaccine within 2 year prior registration Any previous treatment sipuleucelT Any previous treatment ipilimumab ( Yervoy [ TM ] , MDX010 , MDX101 ) denosumab ( Xgeva [ TM ] ) Pathologic longbone fracture , imminent pathologic longbone fracture ( cortical erosion radiography &gt; 50 % ) , spinal cord compression Known malignancy prostate cancer likely require treatment within 6 month registration A history allergic reaction attribute compound similar chemical biologic composition sipuleucelT GMCSF More 2 chemotherapy regimen time prior registration Treatment chemotherapy within 90 day registration Received granulocyte colonystimulating factor ( GCSF ) GMCSF within 90 day prior registration Treatment follow medication intervention within 28 day registration : Systemic corticosteroid . Use inhale , intranasal , intraarticular , topical steroid acceptable , short course ( i.e. , ≤ 1 day ) corticosteroid prevent reaction IV contrast use CT scan . Nonsteroidal antiandrogens ( e.g. , bicalutamide , flutamide , nilutamide ) External beam radiation therapy major surgery require general anesthetic Any systemic therapy prostate cancer include secondary hormonal therapy , megestrol acetate ( Megace® ) , diethylstilbestrol ( DES ) , ketoconazole . Medical castration therapy exclusionary . Immunosuppressive therapy Treatment investigational product Any infection require parenteral antibiotic therapy cause fever ( temperature &gt; 100.5°F 38.1°C ) within 7 day prior registration . Any medical intervention condition , opinion Investigator Dendreon Medical Monitor , could compromise adherence study requirement otherwise compromise study 's objective .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>prostate</keyword>
	<keyword>immune therapy</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>vaccine</keyword>
	<keyword>dendritic cell</keyword>
	<keyword>antigen-presenting cell</keyword>
	<keyword>antigen present cell</keyword>
	<keyword>cancer vaccine</keyword>
	<keyword>PSA</keyword>
	<keyword>prostatic adenocarcinoma</keyword>
</DOC>